Thomas,UnitedHealth Group's solid Q1 results were driven by robust Optum and UnitedHealthcare performances. The company's current-year outlook remains intact despite facing headwinds such as the impact of hepatitis C treatments and aggressive pricing in the NY market. With a diverse business portfolio, the management is confident in mitigating these challenges. The stock is likely to react neutrally in the short term. [0]